Methods: We reviewed all 6 MAs of behavioral HIV interventions for drug users published during 2000-2007. We describe the purpose of these MAs and included primary studies (number and publication period) and assess the meta-analytic results.
Results: Each MA comprised 18 to 47 primary studies published during 1970-2004. The 6 MAs covered different primary studies because they covered different research questions or publication periods. The MAs assessed the effect of risk reduction interventions for in- (3 MAs) or out-of (3 MAs) substance-abuse-treatment drug users, using needle exchange programs (1 MA), and enrolling in contingency management of rewards for stopping/avoiding drug use (2 MAs). Summary effects indicated a 20%-30% change in odds of drug and sex risk, measured as increase in protective behaviors or decrease in risky behaviors. More efficacious interventions included skills-training for avoiding risk, and providing interventions to in-treatment drug users later in treatment.
Conclusion: The 6 MAs covered various research questions, interventions, and recruitment and delivery settings, and provided a wide perspective and moderate favorable effect on risk reduction. Meta-analytic evidence highlights the need for developing stronger interventions, linking risk reduction to reduction in HIV transmission, assessing cost-effectiveness of interventions, and implementing evidence-based interventions.
Learning Objectives:
1. Articulate the components of behavioral prevention interventions with drug users and assess their efficacy in reducing HIV-related sex and drug risk behaviors
2. Discuss the advantages of meta-analysis as one technique for understanding the contribution of behavioral and social research to HIV prevention
3. Assess how the different meta-analytic studies can inform development of future primary research, meta-analyses, and evidence-based programs
Keywords: Drug Injectors, Methodology
Qualified on the content I am responsible for because: i prepared this abstract and its content and my co-authors reviewed it, provided comments, and approved it
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
See more of: Alcohol, Tobacco, and Other Drugs
![[ Visit Client Website ]](images/banner.gif)